» Articles » PMID: 23708519

Caloric Restriction Augments Radiation Efficacy in Breast Cancer

Abstract

Dietary modification such as caloric restriction (CR) has been shown to decrease tumor initiation and progression. We sought to determine if nutrient restriction could be used as a novel therapeutic intervention to enhance cytotoxic therapies such as radiation (IR) and alter the molecular profile of triple-negative breast cancer (TNBC), which displays a poor prognosis. In two murine models of TNBC, significant tumor regression is noted with IR or diet modification, and a greater regression is observed combining diet modification with IR. Two methods of diet modification were compared, and it was found that a daily 30% reduction in total calories provided more significant tumor regression than alternate day feeding. At the molecular level, tumors treated with CR and IR showed less proliferation and more apoptosis. cDNA array analysis demonstrated the IGF-1R pathway plays a key role in achieving this physiologic response, and multiple members of the IGF-1R pathway including IGF-1R, IRS, PIK3ca and mTOR were found to be downregulated. The innovative use of CR as a novel therapeutic option has the potential to change the biology of tumors and enhance the opportunity for clinical benefit in the treatment of patients with TNBC.

Citing Articles

The Role of the Microbiome and of Radiotherapy-Derived Metabolites in Breast Cancer.

Herrera-Quintana L, Vazquez-Lorente H, Silva R, Olivares-Arancibia J, Reyes-Amigo T, Pires B Cancers (Basel). 2024; 16(21).

PMID: 39518108 PMC: 11545256. DOI: 10.3390/cancers16213671.


The interplay between autophagy and cGAS-STING signaling and its implications for cancer.

Schmid M, Fischer P, Engl M, Widder J, Kerschbaum-Gruber S, Slade D Front Immunol. 2024; 15:1356369.

PMID: 38660307 PMC: 11039819. DOI: 10.3389/fimmu.2024.1356369.


Calorie Restriction and Time-Restricted Feeding: Effective Interventions in Overweight or Obese Patients Undergoing Radiotherapy Treatment with Curative Intent for Cancer.

Vega C, Barnafi E, Sanchez C, Acevedo F, Walbaum B, Parada A Nutrients. 2024; 16(4).

PMID: 38398802 PMC: 10892811. DOI: 10.3390/nu16040477.


Molecular determinants of immunogenic cell death elicited by radiation therapy.

Galassi C, Klapp V, Yamazaki T, Galluzzi L Immunol Rev. 2023; 321(1):20-32.

PMID: 37679959 PMC: 11075037. DOI: 10.1111/imr.13271.


The impact of microbiome dysbiosis on T cell function within the tumor microenvironment (TME).

DiPalma M, Blattman J Front Cell Dev Biol. 2023; 11:1141215.

PMID: 37009485 PMC: 10063789. DOI: 10.3389/fcell.2023.1141215.


References
1.
Metalli D, Lovat F, Tripodi F, Genua M, Xu S, Spinelli M . The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol. 2010; 176(6):2997-3006. PMC: 2877859. DOI: 10.2353/ajpath.2010.090904. View

2.
Ho V, Leung K, Hsu A, Luk B, Lai J, Shen S . A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res. 2011; 71(13):4484-93. DOI: 10.1158/0008-5472.CAN-10-3973. View

3.
Peyrat J, Bonneterre J, Hecquet B, Vennin P, Louchez M, Fournier C . Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer. 1993; 29A(4):492-7. DOI: 10.1016/s0959-8049(05)80137-6. View

4.
Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B . The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997; 1332(3):F105-26. DOI: 10.1016/s0304-419x(97)00007-3. View

5.
Wu J, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P . Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res. 2006; 12(20 Pt 1):6153-60. DOI: 10.1158/1078-0432.CCR-06-0443. View